
Giacomo Reggiori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8777801/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2013, 86, 336-342.	0.4	168
2	Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2015, 141, 543-553.	1.2	145
3	Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiotherapy and Oncology, 2013, 107, 414-418.	0.3	141
4	Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiation Oncology, 2011, 6, 113.	1.2	107
5	Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. Radiation Oncology, 2013, 8, 171.	1.2	98
6	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Radiation Oncology, 2013, 8, 148.	1.2	91
7	Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiation Oncology, 2014, 9, 91.	1.2	81
8	Radiomics based analysis to predict local control and survival in hepatocellular carcinoma patients treated with volumetric modulated arc therapy. BMC Cancer, 2017, 17, 829.	1.1	77
9	Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. Acta Oncológica, 2012, 51, 618-623.	0.8	76
10	Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up. Radiation Oncology, 2018, 13, 234.	1.2	73
11	Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PLoS ONE, 2019, 14, e0210758.	1.1	58
12	Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. Radiation Oncology, 2012, 7, 16.	1.2	57
13	Lung stereotactic ablative body radiotherapy: A large scale multi-institutional planning comparison for interpreting results of multi-institutional studies. Physica Medica, 2016, 32, 600-606.	0.4	54
14	Dosimetric trade-offs in breast treatment with VMAT technique. British Journal of Radiology, 2017, 90, 20160701.	1.0	51
15	Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis. Medical Physics, 2012, 39, 1112-1118.	1.6	49
16	Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy. Radiotherapy and Oncology, 2019, 133, 220-226.	0.3	49
17	Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiotherapy and Oncology, 2014, 112, 425-429.	0.3	42
18	Stereotactic Body Radiation Therapy (SBRT) for adrenal metastases. Strahlentherapie Und Onkologie, 2011–187–238-244	1.0	41

GIACOMO REGGIORI

#	Article	IF	CITATIONS
19	Pretreatment quality assurance of flattening filter free beams on 224 patients for intensity modulated plans: A multicentric study. Medical Physics, 2012, 39, 1351-1356.	1.6	39
20	Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiation Oncology, 2012, 7, 204.	1.2	38
21	CyberKnife beam output factor measurements: A multi-site and multi-detector study. Physica Medica, 2016, 32, 1637-1643.	0.4	35
22	Interplay effects between dose distribution quality and positioning accuracy in total marrow irradiation with volumetric modulated arc therapy. Medical Physics, 2013, 40, 111713.	1.6	34
23	Plan robustness in field junction region from arcs with different patient orientation in total marrow irradiation with VMAT. Physica Medica, 2015, 31, 677-682.	0.4	34
24	Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy. Acta OncolÃ ³ gica, 2013, 52, 545-552.	0.8	32
25	Evaluation of the dose calculation accuracy for small fields defined by jaw or MLC for AAA and Acuros XB algorithms. Medical Physics, 2016, 43, 5685-5694.	1.6	32
26	Hypofractionated stereotactic radiation therapy in skull base meningiomas. Journal of Neuro-Oncology, 2015, 124, 283-289.	1.4	31
27	Multicenter evaluation of a synthetic single-crystal diamond detector for CyberKnife small field size output factors. Physica Medica, 2016, 32, 575-581.	0.4	30
28	Liver metastases from colorectal cancer: propensity score-based comparison of stereotactic body radiation therapy vs. microwave ablation. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1777-1783.	1.2	28
29	Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. Radiation Oncology, 2013, 8, 176.	1.2	27
30	Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. Journal of Applied Clinical Medical Physics, 2012, 13, 138-147.	0.8	26
31	Evaluation of a synthetic singleâ€crystal diamond detector for relative dosimetry on the Leksell Gamma Knife Perfexion radiosurgery system. Medical Physics, 2015, 42, 5035-5041.	1.6	25
32	Small field output factors evaluation with a microDiamond detector over 30 Italian centers. Physica Medica, 2016, 32, 1644-1650.	0.4	25
33	Flattening filter free beams from TrueBeam and Versa HD units: Evaluation of the parameters for quality assurance. Medical Physics, 2015, 43, 205-212.	1.6	24
34	Characterization of a new unshielded diode for small field dosimetry under flattening filter free beams. Physica Medica, 2016, 32, 408-413.	0.4	22
35	Collimator angle influence on dose distribution optimization for vertebral metastases using	1.6	20
36	Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1795-1800.	1.2	20

GIACOMO REGGIORI

#	Article	IF	CITATIONS
37	In-vivo dosimetry with Gafchromic films for multi-isocentric VMAT irradiation of total marrow lymph-nodes: a feasibility study. Radiation Oncology, 2015, 10, 86.	1.2	19
38	Role of stereotactic body radiation therapy in the treatment of liver metastases: clinical results and prognostic factors. Strahlentherapie Und Onkologie, 2020, 196, 325-333.	1.0	19
39	Applying Lean-Six-Sigma Methodology in radiotherapy: Lessons learned by the breast daily repositioning case. Radiotherapy and Oncology, 2018, 127, 326-331.	0.3	17
40	Technical Note: Multicenter study of TrueBeam FFF beams with a new stereotactic diode: Can a common small field signal ratio curve be defined?. Medical Physics, 2016, 43, 5570-5576.	1.6	15
41	Does deep inspiration breath hold reduce plan complexity? Multicentric experience of left breast cancer radiotherapy with volumetric modulated arc therapy. Physica Medica, 2019, 59, 79-85.	0.4	15
42	Vertebral metastases reirradiation with volumetric-modulated arc radiotherapy. Radiotherapy and Oncology, 2012, 102, 416-420.	0.3	14
43	Dosimetric characterization of small fields using a plastic scintillator detector: A large multicenter study. Physica Medica, 2017, 41, 33-38.	0.4	14
44	Small field correction factors for the IBA Razor. Physica Medica, 2016, 32, 1025-1029.	0.4	13
45	Are pitch and roll compensations required in all pathologies? A data analysis of 2945 fractions. British Journal of Radiology, 2015, 88, 20150468.	1.0	12
46	Use of PTW-microDiamond for relative dosimetry of unflattened photon beams. Physica Medica, 2017, 38, 45-53.	0.4	12
47	AÂradiomic approach to predicting nodal relapse and disease-specific survival in patients treated with stereotactic body radiation therapy for early-stage non-small cell lung cancer Strahlentherapie Und Onkologie, 2020, 196, 922-931.	1.0	12
48	Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?. Radiotherapy and Oncology, 2020, 150, 184-190.	0.3	12
49	Development of an Immobilization Device for Total Marrow Irradiation. Practical Radiation Oncology, 2021, 11, e98-e105.	1.1	10
50	MLC parameters from static fields to VMAT plans: an evaluation in a RT-dedicated MC environment (PRIMO). Radiation Oncology, 2019, 14, 216.	1.2	9
51	Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. Clinical and Experimental Metastasis, 2020, 37, 565-573.	1.7	9
52	Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity. Journal of Cancer Research and Clinical Oncology, 2021, 147, 927-936.	1.2	9
53	Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 608-616.	1.0	8
54	Volumetric modulated arc therapy versus intensity-modulated proton therapy in the postoperative irradiation of thymoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2267-2276.	1.2	7

GIACOMO REGGIORI

#	Article	IF	CITATIONS
55	Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity. Strahlentherapie Und Onkologie, 2021, 197, 133-140.	1.0	6
56	Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1227-1234.	1.2	5
57	Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3619-3625.	1.2	5
58	Radiomics-based prognosis classification for high-risk prostate cancer treated with radiotherapy. Strahlentherapie Und Onkologie, 2022, 198, 710-718.	1.0	5
59	Critical Re-Evaluation of a Failure Mode Effect Analysis in a Radiation Therapy Department After 10 Years. Practical Radiation Oncology, 2021, 11, e329-e338.	1.1	4
60	Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1937-1945.	1.2	3
61	Dosimetric impact of volumetric modulated arc therapy for nasopharyngeal cancer treatment. Reports of Practical Oncology and Radiotherapy, 2021, 26, 101-110.	0.3	3
62	Charlson comorbidity index and G8 in older old adult(≥80Âyears) hepatocellular carcinoma patients treated with stereotactic body radiotherapy. Journal of Geriatric Oncology, 2021, 12, 1100-1103.	0.5	3
63	The Potential Role of Intensity-Modulated Proton Therapy in Hepatic Carcinoma in Mitigating the Risk of Dose De-Escalation. Technology in Cancer Research and Treatment, 2020, 19, 153303382098041.	0.8	2
64	The influence of basic plan parameters on calculated small field output factors – A multicenter study. Physica Medica, 2021, 88, 98-103.	0.4	2